Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Provectus Biopharmaceuticals Inc PVCT

Healthcare
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform... see more

Recent & Breaking News (OTCQB:PVCT)

Trading in Provectus Biopharmaceuticals Common Stock and Warrants Suspended by NYSE MKT

Business Wire October 14, 2016

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 at European Society of Medical Oncology 2016 Congress Now Available Online

Business Wire October 11, 2016

Provectus Biopharmaceuticals Files Registration Statement for Rights Offering to Existing Stockholders

Business Wire October 5, 2016

Provectus Biopharmaceuticals Announces Acceptance of Abstract for Poster Presentation at 31st SITC Annual Meeting

Business Wire September 27, 2016

Provectus Biopharmaceuticals to Present at Rodman & Renshaw’s 18th Annual Global Investment Conference

Business Wire September 8, 2016

Provectus Biopharmaceuticals, Inc. Announces Closing of Public Offering

Business Wire August 30, 2016

Provectus Biopharmaceuticals, Inc. Announces Pricing of Public Offering to Raise $6 Million

Business Wire August 25, 2016

Provectus Biopharmaceuticals, Inc. Announces Proposed Public Offering of Preferred Stock and Warrants

Business Wire August 24, 2016

Provectus Biopharmaceuticals, Inc. Receives Patent from USPTO Related to Rose Bengal Analogs

Business Wire August 23, 2016

Provectus Biopharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results

Business Wire August 9, 2016

Investor Calendar Invites You to the Provectus Biopharmaceuticals Second Quarter 2016 Earnings Conference Call and Webcast Live on Wednesday, August 10, 2016

Accesswire August 9, 2016

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 for Melanoma at European Society for Medical Oncology 2016 Congress

Business Wire August 1, 2016

Philips Launches Ecosystem of Connected Wearable Technologies – for People Who Want to Take Control of Their Health

Business Wire August 1, 2016

Provectus Biopharmaceuticals Will Hold Its 2016 Second Quarter Business Update Conference Call on Wednesday, August 10, 2016, at 4 PM Eastern Daylight Time

Business Wire July 20, 2016

Provectus Biopharmaceuticals Receives Patent Allowance for Use of Halogenated Xanthenes in Pharmaceutical Compositions and as Medicaments

Business Wire July 18, 2016

Provectus Biopharmaceuticals Establishes Australian Subsidiary

Business Wire July 14, 2016

Provectus Biopharmaceuticals Announces PV-10 Data Discussed at 6th European Post-Chicago Melanoma/Skin Cancer Meeting

Business Wire July 13, 2016

Provectus Biopharmaceuticals Announces Acceptance of Abstract for Poster Presentation at European Society for Medical Oncology 2016 Congress

Business Wire July 12, 2016

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 at Annual Meeting of American Society of Clinical Oncology Now Available Online

Business Wire June 9, 2016

Provectus Biopharmaceuticals Announces Publication of Article on PV-10 for In-Transit Melanoma in Journal of Surgical Oncology

Business Wire June 7, 2016